Soricimed’s Jack Stewart receives prestigious New Brunswick BioSciences Achievement Award

Jack Stewart, Chairman and Chief Scientific Officer of Soricimed Biopharma Inc., is this year’s recipient of the prestigious New Brunswick BioSciences Achievement Award. The presentation was made at the 2011 New Brunswick BioScience Celebration and Banquet held at Mount Allison University as part of National Biotechnology Week. Left to right: Doug Robertson, President and CEO, Tech South East; Paul Gunn, President and CEO, Soricimed Biopharma Inc.; Jack Stewart, Chairman and Chief Scientific Officer, Soricimed Biopharma Inc.; Hon. Michael Olscamp, MLA for Tantramar and Minister of Agriculture, Aquaculture and Fisheries; John Argall, Executive Director, BioAtlantech. (Photo by Daniel St. Louis)

NEWS RELEASE

September 22, 2011
For immediate release

Soricimed Chairman and Chief Scientific Officer Jack Stewart receives prestigious New Brunswick BioSciences Achievement Award

SACKVILLE, N.B. – Professor Emeritus Jack Stewart, Chairman and Chief Scientific Officer of Soricimed Biopharma Inc., is this year’s recipient of the prestigious New Brunswick BioSciences Achievement Award. The presentation was made at the 2011 New Brunswick BioScience Celebration and Banquet held at Mount Allison University as part of National Biotechnology Week.

Launched in 2004, the New Brunswick BioSciences Achievement Award has celebrated outstanding contributions to the global scientific community and/or socio-economic improvements through bio-science. BioAtlantech leads this annual award in tandem with its partners.

The evaluation criteria also account for the candidate’s collegiality and leadership. A panel of judges from New Brunswick’s bio-science community evaluated half a dozen exceptional candidates for the 2011 Bio-Sciences Achievement Award before deciding on Stewart as the chosen recipient.

“Receiving this award is a great honour for me, personally,” Stewart said. “I would be remiss, however, if I did not also recognize my many colleagues at Soricimed and Mount Allison University for their partnership, collaboration and friendship over the years. Without it, this award would not have been possible.”

“I would like to sincerely thank BioAtlantech, its partners and the distinguished panel of judges for choosing me as the 2011 recipient of this award,” he said.

Soricimed President and CEO Paul Gunn was elated upon hearing of Stewart’s award. “On behalf of everyone at Soricimed, we are thrilled to see Jack receive this well-deserved recognition for his hard work over his long and illustrious career in research. We are convinced that the research he and his team are carrying out at Soricimed will save many lives in the years to come. He is certainly deserving of this recognition by his peers in the scientific community.”

Stewart was full professor in the biochemistry program at Mount Allison University until his early retirement in 2009. He has twice been the recipient of the institution’s Paul Paré Imasco Award for excellence in teaching and excellence in research and recently granted Professor Emeritus status.

The major focus of Stewart’s lab was metabolic adaptations in animals, and protein biochemistry and was supported by the Natural Sciences and Engineering Research Council and the Heart and Stroke Foundation. Early soricidin research was supported by the Canadian Institutes of Health Research.

Stewart is the senior author on six patents and has published extensively with more than 30 peer-reviewed publications, dozens of presentations and lectures, presentations at academic conferences, and industry recognition awards.

About BioAtlantech

BioAtlantech, the lead sponsor of the 2011 Bio-Sciences Achievement Award, is the lead agency for New Brunswick’s bio-industries. Working with government and the private sector, the corporation:

• builds and enhances new and existing businesses in New Brunswick’s biosciences sectors
• supports technology transfer from public institutions to the private sector
• offers services in competitive technical intelligence and business plan development
• assists partners in company recruitment
• assists partners in policy development
• manages strategic projects
• co-ordinates networking opportunities for the sector.

About Soricimed

Soricimed Biopharma Inc. is a private drug development company created in 2005 by Professor Jack Stewart and Paul Gunn following the discovery and development of a proprietary peptide, soricidin. Soricidin is the basis for Soricimed Biopharma Inc.’s targeted cancer management program focused on an ovarian cancer therapeutic and a companion diagnostic.

Using focused innovative strategies in collaboration with major world-class cancer research institutions, Soricimed’s drugs have demonstrated a capability to reduce cancer cell viability and induce apoptosis (in vitro) and to reduce human tumour volume (in vivo) with no demonstrable serious side-effects.

Soricimed receives its funding from a variety of sources, including private investors, the Government of Canada and the Province of New Brunswick.

-30-

Media contact:

Paul Gunn
President and CEO
Soricimed Biopharma Inc.
(506) 872-2181
pgunn@soricimed.com
www.soricimed.com

Sorry, comments are closed for this post.